Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Nalpropion Pharmaceuticals LLC
WARNING LETTER
•Nalpropion Pharmaceuticals LLC•September 29, 2020

Nalpropion Pharmaceuticals LLC – FDA Warning Letter, Sep 29, 2020

Record Details

The FDA's Office of Prescription Drug Promotion (OPDP) issued a Warning Letter to Nalpropion Pharmaceuticals LLC concerning a sponsored Google link for CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. The OPDP, along with a complaint from the FDA Bad Ad Program, found that the sponsored link made false or misleading claims about Contrave's risks and efficacy, thereby misbranding the drug under 21 U.S.C. 352(a), (n); 321(n); 331(a) and 21 CFR 202.1(e)(3)(ii); (e)(5).

Specifically, the link presented efficacy claims while entirely omitting critical risk information, including the boxed warning for suicidal thoughts and behaviors, creating a misleading impression of safety. Furthermore, it failed to disclose material information from the FDA-approved indication, such as the requirement for Contrave to be an adjunct to diet and exercise, specific initial BMI criteria, the need for weight-related comorbid conditions, and limitations of use. The promotion also selectively presented favorable efficacy data, implying broader applicability than approved.

These violations are particularly concerning given Contrave's serious, potentially life-threatening risks. OPDP noted a similar issue in a 2017 Untitled Letter to the previous application holder. Nalpropion is required to immediately cease misbranding Contrave and submit a written response by October 7, 2020. The response must detail a comprehensive plan to disseminate truthful, non-misleading corrective messages to the audience that received the violative promotional materials. Failure to comply may lead to FDA regulatory actions like seizure or injunction.

Company
Nalpropion Pharmaceuticals LLC
Inspection date
September 29, 2020
Product type
Drugs
Office
Office of Prescription Drug Promotion
Person
  • Robert Dean (Director)
View Company Profile

ID · 99e96b57-28a7-4b13-9f55-e32dacb08833

Violation Codes6
21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 321(n)21 CFR 202.1(e)(3)(ii)21 CFR 202.1(e)(5)21 U.S.C. 331(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Nalpropion Pharmaceuticals LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.